Massive Selection for Niraparib Tosylate Hydrate - Captopril – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our enterprise since its inception, constantly regards product good quality as organization life, constantly improve production technology, strengthen merchandise high quality and continuously strengthen enterprise total good quality administration, in strict accordance with all the national standard ISO 9001:2000 for Niraparib Tosylate Hydrate, Doxycycline Mono 100mg Tablet, Pregabalin Manufacturer, We invites you and your company to thrive together with us and share a dazzling foreseeable future in world-wide market place.
Massive Selection for Niraparib Tosylate Hydrate - Captopril – CPF Detail:

Description

Captopril (SQ-14534) is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE).

In Vitro

Captopril (SQ-14534) has been shown to have similar morbidity and mortality benefits to those of diuretics and beta-blockers in hypertensive patients. Captopril (SQ-14534) has been shown to delay the progression of diabetic nephropathy, and enalapril and lisinopril prevent the development of nephropathy in normoalbuminuric patients with diabetes[1]. An equimolar ratio of the cis and trans states of Captopril (SQ-14534) exists in solution and that the enzyme selects only the trans state of the inhibitor that presents architectural and stereoelectronic complementarity with its substrate binding groove[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number Sponsor Condition Start Date

Phase

NCT03179163 Penn State University|National Heart, Lung, and Blood Institute (NHLBI) Hypertension,Essential July 20, 2016

Phase 1|Phase 2

NCT03660293 Tanta University Diabetes Mellitus, Type 1 April 1, 2017

Not Applicable

NCT03147092 Centro Neurológico de Pesquisa e Reabiitação, Brazil Hypertension|Blood Pressure February 1, 2018

Early Phase 1

NCT00252317 Rigshospitalet, Denmark Aortic Stenosis November 2005

Phase 4

NCT02217852 West China Hospital Hypertension August 2014

Phase 4

NCT01626469 Brigham and Women´s Hospital Type 2 Diabetes Mellitus May 2012

Phase 1|Phase 2

NCT00391846 AstraZeneca Heart Failure|Ventricular Dysfunction, Left October 2006

Phase 4

NCT00240656 Hebei Medical University Hypertension, Pulmonary October 2005

Phase 1

NCT00086723 Northwestern University|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2003

Phase 1|Phase 2

NCT00663949 Shiraz University of Medical Sciences Diabetic Nephropathy February 2006

Phase 2|Phase 3

NCT01437371 University Hospital, Clermont-Ferrand|Servier|LivaNova Heart Failure August 2011

Phase 3

NCT04288700 Ain Shams University Infantile Hemangioma October 1, 2019

Phase 4

NCT00223717 Vanderbilt University|Vanderbilt University Medical Center Hypertension January 2001

Phase 1

NCT02770378 University of Ulm|Reliable Cancer Therapies|Anticancer Fund, Belgium Glioblastoma November 2016

Phase 1|Phase 2

NCT01761916 Instituto Materno Infantil Prof. Fernando Figueira Preeclampsia January 2013

Phase 4

NCT01545479 Instituto de Cardiologia do Rio Grande do Sul Renal Disease January 2010

Phase 4

NCT00935805 Hospital de Clinicas de Porto Alegre|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil Diabetes Mellitus|Arterial Hypertension July 2006

NCT00742040 The Hospital for Sick Children Heart Disease August 2008

Phase 2

NCT03613506 Wuhan University Radiotherapy Side Effect|Taking Captopril October 25, 2018

Phase 2

NCT00004230 Northwestern University|National Cancer Institute (NCI) Cancer October 1999

Phase 3

NCT00660309 Novartis Type 2 Diabetes Mellitus April 2008

Phase 4

NCT00292162 NHS Greater Glasgow and Clyde Chronic Heart Failure|Atrial Fibrillation January 2007

Not Applicable

NCT01271478 Coordinación de Investigación en Salud, Mexico Inflammation|End-stage Renal Disease August 2009

Phase 4

NCT04193137 Chongqing Medical University Primary Aldosteronism November 30, 2019

NCT00155064 National Taiwan University Hospital Hyperaldosteronism July 2002

Phase 4

NCT01292694 Vanderbilt University|Vanderbilt University Medical Center Hypertension|Pure Autonomic Failure|Multiple System Atrophy March 2011

Phase 1

NCT00917345 National Taiwan University Hospital|Novartis Primary Aldosteronism January 2008

NCT00077064 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Lung Cancer|Pulmonary Complications|Radiation Fibrosis June 2003

Phase 2

Storage

Powder

-20°C

3 years
 

4°C

2 years
In solvent

-80°C

6 months
 

-20°C

1 month

Chemical structure

Captopril

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation


Product detail pictures:

Massive Selection for Niraparib Tosylate Hydrate - Captopril  – CPF detail pictures


Related Product Guide:

The key to our success is "Good Products Good quality, Reasonable Value and Efficient Service" for Massive Selection for Niraparib Tosylate Hydrate - Captopril – CPF , The product will supply to all over the world, such as: Iraq, Armenia, Macedonia, They're durable modeling and promoting well all over the world. Under no circumstances disappearing key functions in a brief time, it's a should for you personally of fantastic quality. Guided by the principle of Prudence, Efficiency, Union and Innovation. the business make an awesome efforts to expand its international trade, raise its enterprise. rofit and improve its export scale. We are confident that we'll have a vibrant prospect and to be distributed all over the world in the years to come.
  • The sales manager is very patient, we communicated about three days before we decided to cooperate, finally, we are very satisfied with this cooperation!
    5 Stars By Karen from Sacramento - 2017.06.29 18:55
    After the signing of the contract, we received satisfactory goods in a short term, this is a commendable manufacturer.
    5 Stars By Althea from Lebanon - 2017.07.07 13:00
    Write your message here and send it to us